NCT04390399Phase 2Active not recruiting

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Study sponsor: ImmunityBio, Inc. · IBRX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2025-10-13Actual
Enrollment · participants328Estimated
Source updated2025-12-15Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 2 fields changed

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

31 Oct 2025

+ After

13 Oct 2025

Check registry source